These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 27378674)

  • 1. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
    Eskelund CW; Kolstad A; Jerkeman M; Räty R; Laurell A; Eloranta S; Smedby KE; Husby S; Pedersen LB; Andersen NS; Eriksson M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Workman CT; Garde C; Elonen E; Brown P; Grønbaek K; Geisler CH
    Br J Haematol; 2016 Nov; 175(3):410-418. PubMed ID: 27378674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
    Geisler CH; Kolstad A; Laurell A; Jerkeman M; Räty R; Andersen NS; Pedersen LB; Eriksson M; Nordström M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Brown P; Elonen E;
    Br J Haematol; 2012 Aug; 158(3):355-62. PubMed ID: 22640180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database.
    Salek D; Vesela P; Boudova L; Janikova A; Klener P; Vokurka S; Jankovska M; Pytlik R; Belada D; Pirnos J; Moulis M; Kodet R; Michal M; Janousova E; Muzik J; Mayer J; Trněný M
    Leuk Lymphoma; 2014 Apr; 55(4):802-10. PubMed ID: 23772666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
    Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
    J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
    Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S
    Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.
    Gressin R; Caulet-Maugendre S; Deconinck E; Tournilhac O; Gyan E; Moles MP; El Yamani A; Cornillon J; Rossi JF; Le Gouill S; Lepeu G; Damaj G; Celigny PS; Maisonneuve H; Corront B; Vilque JP; Casassus P; Lamy T; Colonna M; Colombat P;
    Haematologica; 2010 Aug; 95(8):1350-7. PubMed ID: 20220059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
    Budde LE; Guthrie KA; Till BG; Press OW; Chauncey TR; Pagel JM; Petersdorf SH; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Maloney DG; Gopal AK
    J Clin Oncol; 2011 Aug; 29(22):3023-9. PubMed ID: 21730271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
    Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
    Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
    Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
    Husby S; Ralfkiaer U; Garde C; Zandi R; Ek S; Kolstad A; Jerkeman M; Laurell A; Räty R; Pedersen LB; Pedersen A; Ehinger M; Sundström C; Karjalainen-Lindsberg ML; Delabie J; Clasen-Linde E; Brown P; Cowland JB; Workman CT; Geisler CH; Grønbæk K
    Blood; 2015 Apr; 125(17):2669-77. PubMed ID: 25736311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.
    Holte H; Beiske K; Boyle M; Trøen G; Blaker YN; Myklebust J; Kvaløy S; Rosenwald A; Lingjaerde OC; Rimsza LM; Smeland EB; Scott DW; Kolstad A
    Br J Haematol; 2018 Oct; 183(2):225-234. PubMed ID: 30080252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).
    Geisler CH; Kolstad A; Laurell A; Räty R; Jerkeman M; Eriksson M; Nordström M; Kimby E; Boesen AM; Nilsson-Ehle H; Kuittinen O; Lauritzsen GF; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Brown P; Elonen E;
    Blood; 2010 Feb; 115(8):1530-3. PubMed ID: 20032504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.
    He JS; Chen X; Wei GQ; Sun J; Zheng WY; Shi JM; Wu WJ; Zhao Y; Zheng GF; Huang H; Cai Z
    Medicine (Baltimore); 2019 Jan; 98(1):e13741. PubMed ID: 30608386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
    Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.
    Evens AM; Winter JN; Hou N; Nelson BP; Rademaker A; Patton D; Singhal S; Frankfurt O; Tallman MS; Rosen ST; Mehta J; Gordon LI
    Br J Haematol; 2008 Feb; 140(4):385-93. PubMed ID: 18162124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma.
    Smith SD; Gandhy S; Gopal AK; Reddy P; Shadman M; Till BG; Lynch RC; Kanan S; Cowan A; Low L; Hill BT
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):48-52. PubMed ID: 30409719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.